Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares. View BLCM analyst ratings or view top-rated stocks .

How have BLCM shares performed in 2023?

Bellicum Pharmaceuticals' stock was trading at $0.72 on January 1st, 2023. Since then, BLCM shares have decreased by 72.1% and is now trading at $0.2008. View the best growth stocks for 2023 here .

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $1 million for the quarter.

When did Bellicum Pharmaceuticals' stock split?

Shares of Bellicum Pharmaceuticals reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR) , Alliance Resource Partners (ARLP) , AVEO Pharmaceuticals (AVEO) , CyberArk Software (CYBR) , AcelRx Pharmaceuticals (ACRX) , Gilead Sciences (GILD) , Novavax (NVAX) , Pfizer (PFE) and Inovio Pharmaceuticals (INO) .

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Bellicum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BLCM)

$0.20

0.00 (0.00%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.20
▼
$0.25
50-Day Range: $0.10
▼
$0.32
52-Week Range: $0.06
▼
$1.50

Volume: 11,815 shs
Average Volume: 827,785 shs
Market Capitalization: $1.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

BLCM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLCM Stock News Headlines

December 8, 2023 | benzinga.com

Bellicum Pharmaceuticals Stock (OTC:BLCM), Short Interest Report

December 2, 2023 | americanbankingnews.com

Bellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated at StockNews.com

December 8, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

October 27, 2023 | finance.yahoo.com

Futura Medical plc (FAMDF)

July 13, 2023 | finance.yahoo.com

BLCM - Bellicum Pharmaceuticals, Inc.

June 3, 2023 | fool.com

Bellicum Pharmaceuticals (NASDAQ: BLCM)

May 8, 2023 | investorplace.com

Why Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?

April 18, 2023 | msn.com

Why Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket

December 8, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

April 18, 2023 | benzinga.com

Short Volatility Alert: Bellicum Pharma

March 15, 2023 | msn.com

BLCM Plummets on Stopping Trials of BPX-601 and BPX-603

March 15, 2023 | msn.com

Why Bellicum Pharmaceuticals (BLCM) Stock Is Down 48%

March 14, 2023 | finance.yahoo.com

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

February 24, 2023 | finance.yahoo.com

Why Bellicum Pharmaceuticals Stock Is Plunging Today

February 16, 2023 | finance.yahoo.com

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

January 31, 2023 | finance.yahoo.com

CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2023 | finance.yahoo.com

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

November 13, 2022 | finanznachrichten.de

Bellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

November 10, 2022 | finance.yahoo.com

Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

October 4, 2022 | finance.yahoo.com

Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa

September 15, 2022 | seekingalpha.com

BLCM Bellicum Pharmaceuticals, Inc.

September 1, 2022 | finance.yahoo.com

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 25, 2022 | finance.yahoo.com

Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

August 18, 2022 | finance.yahoo.com

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

August 11, 2022 | finance.yahoo.com

Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update

May 13, 2022 | seekingalpha.com

Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42

May 13, 2022 | finance.yahoo.com

Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update

See More Headlines

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLCM
CUSIP: N/A
CIK: 1358403
Web: www.bellicum.com
Phone: (281) 454-3424
Fax: N/A
Employees: 13
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,970,000.00
Net Margins: N/A
Pretax Margin: -1,492.40%
Return on Equity: -753.03%
Return on Assets: -157.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.04
Quick Ratio: 3.04

Sales & Book Value

Annual Sales: $1.51 million
Price / Sales: 1.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.23 per share
Price / Book: 0.87

Miscellaneous

Outstanding Shares: 9,496,000
Free Float: 8,518,000
Market Cap: $1.91 million
Optionable: Not Optionable
Beta: 1.59

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Charles S. Grass (Age 63)
Principal Accounting Officer
Mr. Joseph Senesac (Age 53)
Senior Vice President of Technical Operations & Quality
Dr. Alan K. Smith Ph.D. (Age 65)
Chief Scientific Officer
Comp: $536.43k

Key Competitors

View All Competitors

BLCM Stock Analysis - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
View BLCM analyst ratings or view top-rated stocks.
How have BLCM shares performed in 2023?: Bellicum Pharmaceuticals' stock was trading at $0.72 on January 1st, 2023. Since then, BLCM shares have decreased by 72.1% and is now trading at $0.2008.
View the best growth stocks for 2023 here.
How were Bellicum Pharmaceuticals' earnings last quarter?: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $1 million for the quarter.
When did Bellicum Pharmaceuticals' stock split?: Shares of Bellicum Pharmaceuticals reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).
When did Bellicum Pharmaceuticals IPO?: (BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.
How do I buy shares of Bellicum Pharmaceuticals?: Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BLCM) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial